Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

Those include its new Alzheimer's drug Leqembi (lecanemab) – another Eisai-partnered therapy that recently became the first in the anti-amyloid class to get full FDA approval – as well as ...

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

One of the most difficult aspects of developing treatments for Alzheimer’s disease is understanding the mechanisms of neuron ... Kisunla from Eli Lilly and Leqembi from Biogen and Esai ...

The international team describes their results and the underlying molecular mechanism in Cell Metabolism. Ergothioneine is a natural compound found in certain fungi such as oyster or shiitake ...

EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population That trio of molecules stands out in the late-stage pipeline because of their novel mechanisms ...

Later on in the call when asked about the possibility of PBM reform, Witty said PBMs were the only effective mechanism across the system that holds the pharmaceutical companies accountable for prices.